VKTX logo

VKTXViking Therapeutics Inc

$29.45
$1.98
(6.33%)
Today
Closed $29.29
$0.16
(0.55%)
After Hours
Updated: 06:35 PM EDT
EarningsJul 29
Mkt Cap$3.63B
Vol2.76M
45

Neutral Sentiment

How do you feel about VKTX?

News
all
press releases
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Down
Key PointsVK2735 is being developed in both subcutaneous and oral forms, and upcoming Phase 1 maintenance trial results are a major catalyst...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Why Is Viking Therapeutics (VKTX) Up 3.2% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
Zacks
News Placeholder
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.18, denoting a +1.64% move from the preceding trading day.
Zacks
News Placeholder
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call
Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.
Stocktwits
News Placeholder
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Zacks
News Placeholder
Don't Buy Viking Therapeutics Stock Until You Read This
Key PointsEnthusiasm for Viking Therapeutics and its weight-loss candidate has come and gone, and for good reason...
Nasdaq News: Markets
News Placeholder
Is Viking Therapeutics a Top Takeover Target?
Key PointsBig pharma still needs additional late-stage obesity drug assets...
Nasdaq News: Markets
News Placeholder
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Zacks
News Placeholder
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Zacks
<
1
2
...
>